Could a common mineral slow Parkinson's? new trial begins

NCT ID NCT06592014

ENROLLING_BY_INVITATION Disease control Sponsor: State University of New York at Buffalo Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether low-dose lithium aspartate, a dietary supplement, can slow the progression of Parkinson's disease. It involves 35 people who have already completed a lithium trial, and they will take lithium for another 24 weeks. Researchers will use brain scans and blood tests to look for changes in key markers of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lithium aspartate (a dietary supplement form of lithium)
What this could lead to: If it works, this could point toward a way to slow Parkinson's disease progression using a low-cost, repurposed supplement.
What could go wrong: This is a small, early-phase open-label trial with no placebo group, so results may be due to chance or bias. Lithium can cause side effects like kidney or thyroid issues, even at low doses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Charcot-Marie-Tooth disease type 1F Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Locations

UBMD Neurology

Williamsville, New York, 14221, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.